NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In ...
the tumors returned, and Sarah traveled back to Boston for further drug treatment, which was not successful. She developed brainmetastases[mə'tæstəsi:z].Her doctors in Boston knew of one more targeted therapy drug...
本研究发现增加新辅助周期数可改善术后显著病理学缓解(MPR)率,有望提高早中期NSCLC的治愈率。 研究解读 本研究在2022年美国ASCO大会上做口头报告,并入选了当年的BEST OF ASCO,并于2023年在《Signal Transduction and Targeted Therapy》(IF:39.3)发表,题目为“Two vs three cycles of neoadjuvant sintilimab plus ...
An analysis of 43 KRAS mutant NSCLC patients who were enrolled in the BATTLE-1 (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial determined that KRAS mutation variants G12C and G12V were significantly associated with worse median PFS compared to other ...
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Critical Issues: Here, we describe how altered replication contributes to the efficacy of HDAC-targeted therapies as well as discuss what knowledge mouse models have provided to our understanding of...
Up-regulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC ... N Chen,W Fang,J Zhan,... - 《Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cance...
crizotinib has been used as a first- or second-line therapy in patients with NSCLC harboring ALK, ROS1, or MET alterations96,98,99. However, due to the rapid emergence of resistance to crizotinib and its weak ability to penetrate the central nervous system (CNS)95,96,100, additional ALK ...
Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and antibody-based therapies, especially for solid tumors. Neoantigens are newly fo
Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are sm...
摘要: Targeted therapies: Tyrosine-kinase inhibitors—new standard for NSCLC therapyNature Reviews Clinical Oncology 7, 618 (2010). doi:10.1038/nrclinonc.2010.168Author: Nagahiro SaijoA clinic ...DOI: 10.1038/nrclinonc.2010.168 被引量: 14 ...